Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer

Abstract Background At least 50% of triple negative breast cancer (TNBC) overexpress the epidermal growth factor receptor, EGFR, which paved the way for clinical trials investigating its blockade. Outcomes remained dismal stemming from mechanisms of resistance particularly the nuclear cycling of EGF...

全面介紹

書目詳細資料

Principais autores:	Brooke N. McKnight, Seongho Kim, Julie L. Boerner, Nerissa T. Viola
格式:	Artigo
語言:	Inglês
出版:	BMC 2020-04-01
叢編:	Breast Cancer Research
主題:	Nuclear EGFR translocation EGFR PET imaging Triple negative breast cancer Src Dasatinib
在線閱讀:	http://link.springer.com/article/10.1186/s13058-020-01270-1
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!